Close
  Indian J Med Microbiol
 

Figure 3: Determination effect of AS on miR-122, miR-221, p53, and RUNX2 levels in osteoblast using real-time polymerase chain reaction and Western blot analysis (*P < 0.05, vs. control group). (a) Astragaloside dose dependently enhanced miR-122 expression compared with controls. (b) Treating with AS dose dependently reduced miR-221 messenger RNA level compared with controls. (c) P53 messenger RNA level showed a stepwise decline as the concentration of astragaloside treatment increased when compared with controls. (d) RUNX2 messenger RNA in cells treated with different dose of astragaloside displayed a stepwise increase compared with controls. (e) AS treatment dose dependently upregulated P53 and RUNX2 protein levels compared with controls

Figure 3: Determination effect of AS on miR-122, miR-221, p53, and RUNX2 levels in osteoblast using real-time polymerase chain reaction and Western blot analysis (*<i>P</i> < 0.05, vs. control group). (a) Astragaloside dose dependently enhanced miR-122 expression compared with controls. (b) Treating with AS dose dependently reduced miR-221 messenger RNA level compared with controls. (c) P53 messenger RNA level showed a stepwise decline as the concentration of astragaloside treatment increased when compared with controls. (d) RUNX2 messenger RNA in cells treated with different dose of astragaloside displayed a stepwise increase compared with controls. (e) AS treatment dose dependently upregulated P53 and RUNX2 protein levels compared with controls